Cross Talks Between CNS and CVS Diseases: An Alliance to Annihilate

Overview

Journal Curr Cardiol Rev

Publisher Bentham Science Publishers

Specialty Cardiology & Vascular Diseases

Date 2024 Mar 5

PMID 38441007

Authors

Shivani Chib

Sushma Devi

Rishabh Chalotra

Neeraj Mittal

Thakur Gurjeet Singh

Puneet Kumar

Randhir Singh

Affiliations

Soon will be listed here.

Abstract

Cardiovascular and neurological diseases cause substantial morbidity and mortality globally. Moreover, cardiovascular diseases are the leading cause of death globally. About 17.9 million people are affected by cardiovascular diseases and 6.8 million people die every year due to neurological diseases. The common neurologic manifestations of cardiovascular illness include stroke syndrome which is responsible for unconsciousness and several other morbidities significantly diminished the quality of life of patients. Therefore, it is prudent need to explore the mechanistic and molecular connection between cardiovascular disorders and neurological disorders. The present review emphasizes the association between cardiovascular and neurological diseases specifically Parkinson's disease, Alzheimer's disease, and Huntington's disease.

References

Ohlmeier C, Saum K, Galetzka W, Beier D, Gothe H . Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data. BMC Neurol. 2019; 19(1):318. PMC: 6905058. DOI: 10.1186/s12883-019-1556-3. View

Hu P, Zhang D, Swenson L, Chakrabarti G, Abel E, Litwin S . Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol. 2003; 285(3):H1261-9. DOI: 10.1152/ajpheart.00108.2003. View

Iorga A, Cunningham C, Moazeni S, Ruffenach G, Umar S, Eghbali M . The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017; 8(1):33. PMC: 5655818. DOI: 10.1186/s13293-017-0152-8. View

Shoaib M, Becker L . A walk through the progression of resuscitation medicine. Ann N Y Acad Sci. 2020; 1507(1):23-36. DOI: 10.1111/nyas.14507. View

Morris G, Puri B, Bortolasci C, Carvalho A, Berk M, Walder K . The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. Neurosci Biobehav Rev. 2021; 125:244-263. DOI: 10.1016/j.neubiorev.2021.02.037. View

Block R, Ray Dorsey E, Beck C, Brenna J, Shoulson I . Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol. 2010; 4(1):17-23. PMC: 2926984. DOI: 10.1016/j.jacl.2009.11.003. View

Foudah A, Devi S, Alam A, Ayman Salkini M, Ross S . Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer's disease in rats: Mechanistic approach to prevent inflammation. Front Pharmacol. 2023; 14:1115721. PMC: 9932024. DOI: 10.3389/fphar.2023.1115721. View

Poitelon Y, Kopec A, Belin S . Myelin Fat Facts: An Overview of Lipids and Fatty Acid Metabolism. Cells. 2020; 9(4). PMC: 7226731. DOI: 10.3390/cells9040812. View

Tabrizi S, Flower M, Ross C, Wild E . Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020; 16(10):529-546. DOI: 10.1038/s41582-020-0389-4. View

10.

Xie S, Karlsson H, Dalman C, Widman L, Rai D, Gardner R . Family History of Mental and Neurological Disorders and Risk of Autism. JAMA Netw Open. 2019; 2(3):e190154. PMC: 6484646. DOI: 10.1001/jamanetworkopen.2019.0154. View

11.

Amanat S, Ghahri S, Dianatinasab A, Fararouei M, Dianatinasab M . Exercise and Type 2 Diabetes. Adv Exp Med Biol. 2020; 1228:91-105. DOI: 10.1007/978-981-15-1792-1_6. View

12.

Ishitsuka K, Kamouchi M, Hata J, Fukuda K, Matsuo R, Kuroda J . High blood pressure after acute ischemic stroke is associated with poor clinical outcomes: Fukuoka Stroke Registry. Hypertension. 2013; 63(1):54-60. DOI: 10.1161/HYPERTENSIONAHA.113.02189. View

13.

Bohlen C, Friedman B, Dejanovic B, Sheng M . Microglia in Brain Development, Homeostasis, and Neurodegeneration. Annu Rev Genet. 2019; 53:263-288. DOI: 10.1146/annurev-genet-112618-043515. View

14.

Magi S, Piccirillo S, Amoroso S, Lariccia V . Excitatory Amino Acid Transporters (EAATs): Glutamate Transport and Beyond. Int J Mol Sci. 2019; 20(22). PMC: 6888595. DOI: 10.3390/ijms20225674. View

15.

Berghauzen-Maciejewska K, Wardas J, Kosmowska B, Glowacka U, Kuter K, Ossowska K . Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats. PLoS One. 2015; 10(3):e0117698. PMC: 4349741. DOI: 10.1371/journal.pone.0117698. View

16.

Yaribeygi H, Farrokhi F, Butler A, Sahebkar A . Insulin resistance: Review of the underlying molecular mechanisms. J Cell Physiol. 2018; 234(6):8152-8161. DOI: 10.1002/jcp.27603. View

17.

Alghareeb S, Alfhili M, Fatima S . Molecular Mechanisms and Pathophysiological Significance of Eryptosis. Int J Mol Sci. 2023; 24(6). PMC: 10049269. DOI: 10.3390/ijms24065079. View

18.

Makkar R, Behl T, Bungau S, Zengin G, Mehta V, Kumar A . Nutraceuticals in Neurological Disorders. Int J Mol Sci. 2020; 21(12). PMC: 7352709. DOI: 10.3390/ijms21124424. View

19.

Hirsch E, Hunot S . Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol. 2009; 8(4):382-97. DOI: 10.1016/S1474-4422(09)70062-6. View

20.

Li W, Serpell L, Carter W, Rubinsztein D, Huntington J . Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein. J Biol Chem. 2006; 281(23):15916-22. DOI: 10.1074/jbc.M511007200. View